← Back to Search

Vasodilator

Oral Minoxidil for Platinum-Resistant Ovarian Cancer

Phase 2
Recruiting
Led By Margaret Liotta, DO
Research Sponsored by Loyola University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Participants must have platinum resistant disease defined as recurrence less than 6 months after initial platinum based treatment.
Participants must have an Eastern Cooperative Group (ECOG) Performance Status (PS) less than or equal to 2.
Must not have
Participants must not have congestive heart failure
Participants must not have brain metastases
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 24 months
Awards & highlights

Summary

This trial is testing oral minoxidil for ovarian cancer that has come back and is resistant to platinum drugs. The goal is to see if it works and if so, how well and with what side effects.

Who is the study for?
This trial is for adults over 18 with recurrent platinum-resistant ovarian cancer, who can take pills and have an ECOG Performance Status of 2 or less. They must not have had chemo or radiotherapy in the last 4 weeks, be on other trials, have heart failure or disease, be on dialysis, have brain metastases, allergies to minoxidil, or uncontrolled high blood pressure.Check my eligibility
What is being tested?
The study tests if oral Minoxidil helps patients with recurrent platinum-resistant ovarian cancer. It looks at how many respond to treatment, time before the disease gets worse again and records any side effects. It also explores whether a genetic factor (Kir6/SUR complex) affects Minoxidil's effectiveness.See study design
What are the potential side effects?
Minoxidil may cause side effects such as fluid retention leading to rapid weight gain; swelling of face, hands, ankles; difficulty breathing; fast heartbeat; nausea; vomiting; breast pain/tenderness; changes in hair growth/loss.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
My cancer came back within 6 months after platinum-based treatment.
Select...
I can take care of myself and am up and about more than half of my waking hours.
Select...
I am 18 years old or older.
Select...
I can take medicine by mouth.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I do not have congestive heart failure.
Select...
I do not have cancer that has spread to my brain.
Select...
My blood pressure is under control.
Select...
I have no history of heart disease.
Select...
I am not on dialysis.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 24 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 24 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Overall response rate (ORR)
Secondary outcome measures
Progression-free survival (PFS)

Side effects data

From 2015 Phase 2 trial • 21 Patients • NCT00876200
56%
Hypertrichosis
11%
Strabismus correction
100%
80%
60%
40%
20%
0%
Study treatment Arm
Minoxidil
Placebo

Trial Design

1Treatment groups
Experimental Treatment
Group I: TreatmentExperimental Treatment1 Intervention
Participants in this arm will be treated with minoxidil. This treatment will be given daily by mouth.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Minoxidil
2011
Completed Phase 2
~170

Research Highlights

Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.
Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
Common treatments for ovarian cancer include chemotherapy agents such as paclitaxel, which stabilizes microtubules and inhibits cell division, and topotecan, which inhibits topoisomerase I, leading to DNA damage and cell death. Pegylated liposomal doxorubicin intercalates DNA and inhibits topoisomerase II, causing apoptosis. Targeted therapies like bevacizumab inhibit vascular endothelial growth factor (VEGF), reducing tumor blood supply. Minoxidil, a potassium channel opener and vasodilator, is being studied for its potential to disrupt cancer cell proliferation by altering cellular ion balance and improving drug delivery through enhanced blood flow. Understanding these mechanisms is crucial for tailoring treatments to improve efficacy and manage resistance in ovarian cancer patients.

Find a Location

Who is running the clinical trial?

Loyola UniversityLead Sponsor
156 Previous Clinical Trials
31,067 Total Patients Enrolled
4 Trials studying Ovarian Cancer
76 Patients Enrolled for Ovarian Cancer
Cures Within ReachOTHER
20 Previous Clinical Trials
1,749 Total Patients Enrolled
Medical University of South CarolinaOTHER
947 Previous Clinical Trials
7,398,034 Total Patients Enrolled
1 Trials studying Ovarian Cancer
150 Patients Enrolled for Ovarian Cancer

Media Library

Minoxidil (Vasodilator) Clinical Trial Eligibility Overview. Trial Name: NCT05272462 — Phase 2
Ovarian Cancer Research Study Groups: Treatment
Ovarian Cancer Clinical Trial 2023: Minoxidil Highlights & Side Effects. Trial Name: NCT05272462 — Phase 2
Minoxidil (Vasodilator) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05272462 — Phase 2
~5 spots leftby Dec 2024